Journal of affective disorders · 2026
Cannabis use and subsequent onset of manic symptoms and bipolar disorder: A systematic review and meta-analysis.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sanjuan-Ortiz Cecilia, Querol Paula, Aymerich Claudia, Laherran Nuria, Ditlevsen Fanny, Navalón Pablo, Rojo-Bofill Luis M, Young Allan H, Arango Celso, Sharma Aditya, Di Forti Marta, Murray Robin M, Correll Christoph U, de Pablo Gonzalo Salazar
Аннотация
BACKGROUND: Bipolar disorder is a disabling psychiatric condition affecting approximately 2% of the population, for which identifying modifiable risk factors prior to illness onset is a research priority. Cannabis use is highly prevalent, yet its role in the development of bipolar-spectrum outcomes remains unclear. Previous reviews have included few studies or combined distinct bipolar-spectrum outcomes, limiting outcome-specific inference.
AIMS: To evaluate the association between cannabis exposure and subsequent incident BD and manic/hypomanic symptoms separately and examine potential moderating factors.
METHODS: Registered (https://osf.io/s38x4/), PRISMA/MOOSE-compliant systematic review and meta-analysis of PubMed and Web of Science from inception to October 2025. We included longitudinal observational studies comparing cannabis-exposed and unexposed individuals without prior BD and assessing subsequent bipolar-spectrum outcomes. We meta-analysed studies with extractable data, calculating the unadjusted risk ratios (RRs) for incident BD and manic/hypomanic symptoms. Random-effects meta-analyses, heterogeneity analyses, subgroup analyses and meta-regressions were performed. Study quality was appraised using the Newcastle-Ottawa Scale (NOS).
RESULTS: Nineteen studies were included (total N = 6,960,517; mean age 23.8 ± 11.8 years; 49% female). Cannabis use was associated with increased risk of BD (RR = 2.46, 95% CI = 1.57-3.84; k = 8; N = 206.572) and manic/hypomanic symptoms (RR = 2.11, 95% CI = 1.07-4.18; k = 6; N = 57,243). Moderator analyses identified significant clinical and methodological sources of heterogeneity. NOS scores ranged from 6 to 9, indicating good to high methodological quality.
CONCLUSION: Cannabis use was associated with an increased risk of subsequent bipolar-spectrum outcomes. Routine evaluation of cannabis use alongside prevention strategies, to delay initiation and reduce use, may warranted.
AIMS: To evaluate the association between cannabis exposure and subsequent incident BD and manic/hypomanic symptoms separately and examine potential moderating factors.
METHODS: Registered (https://osf.io/s38x4/), PRISMA/MOOSE-compliant systematic review and meta-analysis of PubMed and Web of Science from inception to October 2025. We included longitudinal observational studies comparing cannabis-exposed and unexposed individuals without prior BD and assessing subsequent bipolar-spectrum outcomes. We meta-analysed studies with extractable data, calculating the unadjusted risk ratios (RRs) for incident BD and manic/hypomanic symptoms. Random-effects meta-analyses, heterogeneity analyses, subgroup analyses and meta-regressions were performed. Study quality was appraised using the Newcastle-Ottawa Scale (NOS).
RESULTS: Nineteen studies were included (total N = 6,960,517; mean age 23.8 ± 11.8 years; 49% female). Cannabis use was associated with increased risk of BD (RR = 2.46, 95% CI = 1.57-3.84; k = 8; N = 206.572) and manic/hypomanic symptoms (RR = 2.11, 95% CI = 1.07-4.18; k = 6; N = 57,243). Moderator analyses identified significant clinical and methodological sources of heterogeneity. NOS scores ranged from 6 to 9, indicating good to high methodological quality.
CONCLUSION: Cannabis use was associated with an increased risk of subsequent bipolar-spectrum outcomes. Routine evaluation of cannabis use alongside prevention strategies, to delay initiation and reduce use, may warranted.